# OnCo record ratify (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ratify/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ratify", "NCT00651261" ;
  schema:name "RATIFY (CALGB 10603)"@en ;
  schema:description "The trial that made FLT3 the first targetable mutation in AML: adding midostaurin to chemotherapy tripled median survival."@en ;
  schema:url <https://onco.cc/trials/ratify/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00651261>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1614359> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2008-04" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-flt3/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/flt3/> ;
  onco:drugs <https://onco.cc/drugs/midostaurin/>, <https://onco.cc/drugs/cytarabine-7-3/> ;
  onco:companies <https://onco.cc/companies/alliance-oncology/>, <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/flt3-itd-allelic-ratio/>, <https://onco.cc/terms/eln-risk/> ;
  onco:people <https://onco.cc/people/richard-stone/> .